Epichem contract to boost revenues at PharmAust
PharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative (DNDi) (www.dndi.org).
PharmAust is a clinical-stage oncology company, and this contract will see Epichem continue to provide synthetic and medicinal chemistry expertise to support DNDi’s drug discovery projects aimed at developing new treatments for neglected diseases, until 31 December, 2020.
Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for more than 16 years.
The subsidiary has newly constructed purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates.
The group also has a rapidly growing catalogue of pharmaceutical reference standards.
Epichem’s progress and increasingly prominent profile was recognised in 2019 when it won the WA Industry Export Award 2019 for International Health.
Helps to offset Unity revenue impact
The contract extension is expected to generate up to $1.24 million in revenues for Epichem during 2020.
PharmAust previously advised that Epichem’s budgeted revenues for fiscal 2020 were $4.2 million subject to the continuation of existing contracts.
Following on from UNITY Biotechnology Inc. ending its contract with Epichem due to funding issues at Unity (advised yesterday) and DNDi extending its contact by an additional year, the net result is that Epichem’s projected revenue forecast for fiscal 2020 is now $3.34 million.
This boost in revenues could provide some share price support following yesterday’s decline on the back of the Unity related news.
Notwithstanding this recent retracement, it should be noted that shares in PharmAust have increased more than 170% over the last 12 months, and the September high of 16 cents represented a near five-fold increase in 2019.
There is the potential for further share price accretion in 2020 as the company continues phase II trials with its lead drug candidate monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway, a key driver of cancer.
Commenting on the contract extension and underlining the long established relationship with DNDi, Epichem’s chief executive Mr Colin La Galia said, “We are delighted the contract with DNDi has been renewed and excited by what we can achieve together in partnership to deliver the expected outcomes with our dedicated team of chemists.
‘’This will mark our twelfth year with DNDi supporting their important work and we look forward to continuing our long-standing relationship with them.”
PharmAust’s chairman Dr Roger Aston said, “It is tremendous that Epichem has secured a further extension to this work with such a leading research and development organisation as DNDi.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.